Candida Auris is not only a concerning fungal pathogen due to its sudden global emergence, but also due to its inherent resistance to disinfection and antifungal drugs. It has posed a remarkable challenge to eradicate, resulting in hospital outbreaks across the world. With high mortality, this fungal pathogen requires an innovative solution to reduce its mortality via improving disinfection and treatment. We explored various methods and crafted a work package plan to create a solution to improve the efficiencies of antifungal drug delivery and microbubble targeting.
Developing Ultrasound-Responsive Microbubble for Treating Topical C. Auris Biofilm Infections
C. auris is a worrying public health threat due to its high mortality, rate of transmission and resistance against traditional antifungal treatments. Therefore, we hope to circumvent its resistance by utilising ultrasound activated microbubble delivery mechanisms to improve current treatments.
Like
Be the first to like this
Zi Jian Lau
(He/Him)
Cancer Biomedicine BSc, University College London
I am a first-generation university student with an oncology degree and a bioengineering background. I am passionate about translational medicine, patient and public involvement, medical education and quality-of-life research. I have a strong research interest in exploring drug delivery methodologies to reduce treatment toxicity and increase the efficacy of anti-cancer therapeutics, namely through nanoparticles and micro-bubbles. With my research, I aim to improve cancer patients' quality of life, allowing them to make informed decisions about their goals and expectations. Recent research includes quantifying NONOate efficacy in bacterial biofilms and identifying novel synthetic lethalities in chemoresistant tumours via CRISPR-Cas9 screens.
I am an incoming Graduate Entry Medicine student at Magdalen College, University of Oxford.
Please sign in
If you are a registered user on Laidlaw Scholars Network, please sign in